Non small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States and worldwide. Unfortunately, standard therapies remain inadequate. An increased understanding of the molecular biology of lung cancer biology is required to develop more effective new therapies. In this report, we show that the Wnt pathway is activated through Dishevelled (Dvl) overexpression in NSCLC. Analysis of freshly resected tumors and lung cancer cell lines demonstrate that Dvl-3, a critical mediator of Wnt signaling, is overexpressed. Specifically, Dvl-3 was overexpressed significantly in 75% of fresh NSCLC microdissected samples compared to control paired matched normal lung samples. To evaluate the biological significance of Wnt signaling and, in particular, Dvl function in lung cancer, we transfected siRNA (designed to inhibit selectively human Dvl-1, -2, and -3), to the NSCLC cell line H1703, which is known to have bcatenin-mediated Tcf-dependent transcriptional activity. Here, we demonstrate that Dvl-specific siRNA treatment in H1703 decreases significantly Dvl and b-catenin expression, resulting in reduction of Tcf-dependent transcriptional activity, and, importantly, growth inhibition. Taken together, these data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation and cell growth in NSCLC.
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Introduction, results, and discussion
Lung cancer is the leading cause of cancer deaths in the United States and worldwide, with 4170 000 newly diagnosed cases each year in the US and nearly million cases worldwide (Minna, 1998) . Despite progress in the multimodality treatment of lung cancer in the past several decades, the 5-year survival rate for lung cancer remains poor at o15% (Minna, 1998) . Surgery, chemotherapy, and radiation have been used with generally unsatisfactory results in advanced disease. Even completely resected early stage (stage I) lung cancer has a cure rate of only 60-70%, significantly less than other early stage I cancers. Improvement in the efficacy of lung cancer treatment is a major public health goal. New therapies based on a better understanding of the biology of lung cancer are necessary. Lung cancers are divided into two major histological classes: non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC (75-80% of all lung cancers) consists of three major types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (Sekido et al., 1998) . Lung adenocarcinomas and squamous cell carcinomas represent 60-70% of all lung cancers. The molecular pathogenesis of lung cancer includes alteration of expression and function of multiple genes including dominant oncogenes and recessive oncogenes/tumor-suppressor genes, alterations in growthregulatory signaling pathways, and abnormalities in other pathways.
We and others have investigated the role of the Wnt pathway and identified Wnt signaling in thoracic malignancies. Activation of Wnt signaling appears to play an important role in carcinogenesis (Morin, 1999; Polakis, 2000) . Recently, we found that overexpression of Dishevelled (Dvl), which is a critical mediator of Wnt signaling, is a dominant event in another thoracic malignancy, namely malignant pleural mesothelioma (You et al., 2001) . In mesothelioma, it appears to induce tumorigenicity via a canonical Wnt signaling pathway. Wnt signaling to date has been reported to be occasionally involved in lung carcinogenesis (Sunaga et al., 2001; Ueda et al., 2001; Hommura et al., 2002; Winn et al., 2002) . Interestingly, a recent report identified Wnt signaling in lung cancer cell lines that corroborated active canonical Wnt signaling (Winn et al., 2002) . Most of these reports, however, have focused on b-catenin activity only to evaluate the activity of Wnt signaling. Owing to our observation that upstream events like Dvl activation play a critical role in mesothelioma growth, we sought to determine if Dvl expression might also be relevant in NSCLC. In this paper, we demonstrate that Dvl-3 is overexpressed in freshly resected NSCLC and established NSCLC cell lines. Furthermore, we show that Wnt signaling through canonical b-catenin pathways appears to be due to upstream events such as Dvl overexpression.
We analysed Dvl expression and function in order to evaluate the function of Wnt signaling in NSCLC. Eight NSCLC fresh tumors (four squamous cell and four adenocarcinomas) and their autologous matched normal lung tissue were obtained from patients undergoing resection of their tumors as part of their treatment for early stage I NSCLC (IRB approval H8714-15319-04). Patients had not received any prior treatment (i.e. chemotherapy, etc.). Western blot analysis of these fresh microdissected samples showed that in 75% of all cancer cells tested (3/4 squamous, and 3/4 adeno, respectively), Dvl-3 was overexpressed, while the corresponding matched normal microdissected lung tissues failed to show expression of Dvl-3 (Figure 1 ). Dvl-1 or -2 expression was not found in NSCLC.
In order to examine Dvl function further, we synthesized small interfering RNA (siRNA) of Dvls, capable of suppressing all Dvl-1, -2, and 3, simultaneously (Li et al., 2002) . We tested the function of Dvl in the lung cancer cell line H1703 by treatment with Dvl siRNA and control siRNA. We chose H1703, because it has Dvl-3 expression, and it has been also demonstrated to have Tcf-dependent transcriptional activity of bcatenin (Winn et al., 2002) . After siRNA treatment, expression of dvl-3 was suppressed, while Dvl-1 and -2 remained unexpressed (Figure 2a) . Importantly, bcatenin expression decreased accordingly in treated cells, which was accompanied by a significant reduction in Tcf-dependent transcriptional activity (Po0.05) (Figure 2b ). Lastly, siRNA of Dvls inhibited H1703 cell growth in 24-well plates significantly (Po0.05) (Figure 3 ). In addition, colony formation in 100-mm dishes was also suppressed significantly (Po0.05) (Figure 4) . In contrast, in other cell lines with lower level Dvl expression compared to that in H1703, such as . The whole-cell lysate aliquots (20 mg) were separated on 4-15% gradient SDS-polyacrylamide gels and transferred to Immobilon-P (Millipore, Bedford, MA, USA) membranes for Western blotting. Antigen-antibody complexes were detected by ECL blotting analysis system (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The following primary antibodies were used: Dvl-1 (3F12), Dvl-2 (10B5), Dvl-3 (4D3) (all Santa Cruz Biotechnology, Santa Cruz, CA, USA), and b-actin (Sigma Chemical Co., St Louis, MO, USA). Three squamous cell carcinomas (cases 1, 3, and 4) and three adenocarcinomas (cases 5, 6, and 8) showed higher expression of Dvl-3 compared with their matched normal lung tissues. In contrast, the expression of Dvl-1 or -2 was not found in NSCLC. NIH-H513 transfected with wildtype mouse Dvl-1 and H290 (mesothelioma cell lines from NIH Frederick, MD, USA) were used as the positive controls for Dvl-1 and -2, respectively The reduction of Dvl-3 expression in NCI-H1703 and SW480 by siRNA to Dvl. The sequences of the siRNA were determined to target human Dvl-1, -2, and -3 (Li et al., 2002) . The NSCLC cell line, NCI-H1703, and the colon cancer cell line, SW480, were obtained from American Type Culture Collection (Manassas, VA, USA), and were cultured in RPMI 1640 complete media containing 10% fetal bovine serum. The siRNAs targeted human Dvl-1, -2, and Dvl-3 (Lane 3), and the control siRNA (SilencerTM Negative Control 1 siRNA, Ambion, Austin, TX, USA) (Lane 2) were transfected using oligofectamine (Invitrogen, Carlsbad, CA, USA) following the protocol provided by Tuschl (www.mpibpc.gwdg.de/ abteilungen/100/105/sirna.html). Transfected cells were collected 72 h later to extract protein for Western blot analysis using Dvl-3 (4D3) (Santa Cruz Biotechnology). Cytoplasmic fractions were prepared for b-catenin (Tranduction Laboratories, Lexington, KY, USA) according to a protocol described previously (Shimizu et al., 1997) . After 72 h, expression of Dvl-3 was reduced markedly to trace levels in both H1703 and SW480. In H1703, cytosolic bcatenin was reduced by the Dvl siRNA, but in SW480 cytosolic bcatenin was not affected. Lane 1 served as control without siRNA transfection. (b) Suppression of Tcf/b-catenin transcriptional activity by siRNA of Dvl. Cells were transfected with the Dvl siRNA (white bars) or the negative control siRNA (black bars) in 24-well plates, and 2 days later, with 0.25 mg of the Tcf reporter construct, pTOPFLASH (kindly provided by H Clevers), and the internal control plasmid pRL-TK (Promega, Madison, WI, USA) using LipofectAmine Plus reagent (Invitrogen). The cells were incubated for 36 h at 371C, washed with PBS, and then lysed to measure luciferase reporter gene expression by dual-luciferase reporter assay system (Promega). The luciferase activity was normalized to Renilla luciferase activity. In H1703, TOPFLASH activity was suppressed significantly (Po0.05) after transfection of the siRNA of Dvl, compared with that of the control siRNA. In contrast, SW480 showed no difference in TOPFLASH activity between transfection of the control and the Dvl siRNA. Results are presented as the average þ s.d. Experiments performed in triplicate. Statistical comparisons were made with a two-sided Student's ttest. A P-value of less than 0.05 was considered to be statistically significant Dvl overexpression in non small cell lung cancer K Uematsu et al A549 (a lung cancer cell line) and SW480 (a colon cancer cell line with aberrant activation in the Wnt signaling pathway due to APC mutation), cell growth was unaffected by the Dvl siRNA.
In the Wnt/b-catenin pathway, Dvl links Wnt/Fz engagement to the inactivation and dissolution of a cytoplasmic protein complex (the destruction complex) that phosphorylates b-catenin, leading to its polyubiquitination and degradation by the 26S proteasome (Wharton, 2003) . Wnt/Fz binding leads to b-catenin accumulation, nuclear translocation, and interaction with lymphoid enhancer-binding factor/T-cell-specific transcription factor family sequence-specific DNAbinding proteins to regulate the expression of genes that harbor Wnt-responsive sequence elements (Brantjes et al., 2002) . In addition, the latest data suggest that Dvl proteins organize dynamic, pathway-specific subcellular signaling complexes that ensure correct information routing, signal amplification, and dynamic control through feedback regulation (Wharton, 2003) . Our data showed that 75% NSCLC tumors (3/4 squamous and 3/ 4 adeno, respectively) had Dvl-3 overexpression. Furthermore, we found that five of six NSCLC tumors with Dvl-3 expression showed higher expression of Wnt-1 or Wnt-2 compared to matched normal tissues by Western blot analysis. These findings indicate that upstream events may lead to Dvl overexpression and Wnt activation. Therefore, Dvl overexpression in fresh NSCLC tumors compared to matched normal lung tissue highlights aberrant or de-repressed upstream signaling in these tumors.
The fact that siRNA-mediated inhibition of Dvl expression decreased b-catenin-mediated Tcf transcription in cell line H1703 suggests that Dvl overexpression is critical to the canonical Wnt/b-catenin pathway in some lung cancer cell lines. In contrast, a colon cancer cell line, SW480, which has activation of Wnt/b-catenin as a result of APC mutation, showed persistently high bcatenin-mediated Tcf activation despite significant depletion of Dvl by siRNA. This highlights the fact that different tumors and cancer cell lines can exploit Wnt signaling, through different points in the signaling cascade. Furthermore, destruction of Dvl suppressed cell growth and colony formation in H1703. These findings indicate that aberrant upstream events in Wnt signaling may be related to tumorigenesis in NSCLC. We suggest that in NSCLC cells, in which APC and bcatenin mutations are exceedingly rare (Sunaga et al., 2001; Ueda et al., 2001) , as opposed to colon cancer cell lines (like SW480), aberrant upstream events lead to Dvl overexpression and transcriptional activity of b-catenin.
Degradation of Dvl by siRNA resulted in growth suppression in H1703, but not in A549. They are both squamous cell lung cancer cell lines, but H1703 has mutational inactivation of p53, and A549 has wild-type p53 (Brognard and Dennis, 2002) . Recently, Matsuzawa and Liu demonstrated that Siah-1 links the p53 pathway to b-catenin and promotes its degradation (Liu et al., 2001; Matsuzawa and Reed, 2001) . Furthermore, p53 can induce Dkk-1, an inhibitor of the Wnt signaling pathway (Wang et al., 2000) . In hepatocellular carcinoma, wild-type b-catenin accumulation has been shown to be associated with mutational inactivation of p53 gene (Cagatay and Ozturk, 2002) . Thus, p53 status may explain, in part, the discrepancy in Dvl function between the two squamous cell lung cancer cell lines tested. It is also possible that the effect of Dvl siRNA in these cells is related to the relative quantity of Dvl expression (i.e. higher in p53 mutant cells). Experiments are in progress to clarify the relationship between p53 status, b-catenin expression and its transcriptional activity, and other noncanonical Wnt signaling pathway in lung cancer cell lines.
In conclusion, our data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation in NSCLC and, in particular, that Dvl overexpression is prevalent, as a result of activated upstream signaling. These findings identify components of Wnt signaling, such as Dvl overexpression, as possible therapeutic targets for the development of novel molecular treatments for lung cancer.
